
A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab not only had fewer bone complications, but they took longer to develop compared with Zometa, reported researchers of a phase 3 study presented Thursday at the San Antonio Breast Cancer Symposium.






